These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 38890728)

  • 21. Multiply robust estimation of principal causal effects with noncompliance and survival outcomes.
    Cheng C; Guo Y; Liu B; Wruck L; Li F; Li F
    Clin Trials; 2024 May; ():17407745241251773. PubMed ID: 38813813
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Applying optimal model selection in principal stratification for causal inference.
    Odondi L; McNamee R
    Stat Med; 2013 May; 32(11):1815-28. PubMed ID: 23042517
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Model misspecification sensitivity analysis in estimating causal effects of interventions with non-compliance.
    Jo B
    Stat Med; 2002 Nov; 21(21):3161-81. PubMed ID: 12375297
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Principal stratification with predictors of compliance for randomized trials with 2 active treatments.
    Roy J; Hogan JW; Marcus BH
    Biostatistics; 2008 Apr; 9(2):277-89. PubMed ID: 17681993
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Assessing the ratio of means as a causal estimand in clinical endpoint bioequivalence studies in the presence of intercurrent events.
    Lou Y; Jones MP; Sun W
    Stat Med; 2019 Nov; 38(27):5214-5235. PubMed ID: 31621943
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Estimation of causal effects in clinical endpoint bioequivalence studies in the presence of intercurrent events: noncompliance and missing data.
    Lou Y; Jones MP; Sun W
    J Biopharm Stat; 2019; 29(1):151-173. PubMed ID: 29995564
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nonparametric inference of complier quantile treatment effects in randomized trials with imperfect compliance.
    Mao L
    Biostat Epidemiol; 2022; 6(2):249-265. PubMed ID: 37551295
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Principal stratification for quantile causal effects under partial compliance.
    Sun S; Nešlehová JG; Moodie EEM
    Stat Med; 2024 Jan; 43(1):34-48. PubMed ID: 37926675
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Causal inference accounting for unobserved confounding after outcome regression and doubly robust estimation.
    Genbäck M; de Luna X
    Biometrics; 2019 Jun; 75(2):506-515. PubMed ID: 30430543
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessing complier average causal effects from longitudinal trials with multiple endpoints and treatment noncompliance: An application to a study of Arthritis Health Journal.
    Guo L; Qian Y; Xie H
    Stat Med; 2022 Jun; 41(13):2448-2465. PubMed ID: 35274333
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Collaborative double robust targeted maximum likelihood estimation.
    van der Laan MJ; Gruber S
    Int J Biostat; 2010 May; 6(1):Article 17. PubMed ID: 20628637
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Double Robust Efficient Estimators of Longitudinal Treatment Effects: Comparative Performance in Simulations and a Case Study.
    Tran L; Yiannoutsos C; Wools-Kaloustian K; Siika A; van der Laan M; Petersen M
    Int J Biostat; 2019 Feb; 15(2):. PubMed ID: 30811344
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A causal model for longitudinal randomised trials with time-dependent non-compliance.
    Becque T; White IR; Haggard M
    Stat Med; 2015 May; 34(12):2019-34. PubMed ID: 25778798
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Likelihood methods for treatment noncompliance and subsequent nonresponse in randomized trials.
    O'Malley AJ; Normand SL
    Biometrics; 2005 Jun; 61(2):325-34. PubMed ID: 16011678
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A comparison of methods for estimating the causal effect of a treatment in randomized clinical trials subject to noncompliance.
    Little RJ; Long Q; Lin X
    Biometrics; 2009 Jun; 65(2):640-9. PubMed ID: 18510650
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Estimating causal effects from a randomized clinical trial when noncompliance is measured with error.
    Boatman JA; Vock DM; Koopmeiners JS; Donny EC
    Biostatistics; 2018 Jan; 19(1):103-118. PubMed ID: 28605411
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Principal stratification analysis of noncompliance with time-to-event outcomes.
    Liu B; Wruck L; Li F
    Biometrics; 2024 Jan; 80(1):. PubMed ID: 38281770
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multiple imputation methods for treatment noncompliance and nonresponse in randomized clinical trials.
    Taylor L; Zhou XH
    Biometrics; 2009 Mar; 65(1):88-95. PubMed ID: 18397338
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Two-step estimation in ratio-of-mediator-probability weighted causal mediation analysis.
    Bein E; Deutsch J; Hong G; Porter KE; Qin X; Yang C
    Stat Med; 2018 Apr; 37(8):1304-1324. PubMed ID: 29322536
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.